Marshall Wace, LLP Cara Therapeutics, Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.83 - $4.94 $376,769 - $657,681	133,134 New	133,134 $376,000
Q2 2021 Aug 13, 2021	SELL	$12.38 - $29.19 $793,545 - $1.87 Million	-64,099 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$15.07 - $21.71 $965,971 - $1.39 Million	64,099 New	64,099 $1.39 Million
Q4 2020 Feb 16, 2021	SELL	$12.72 - $16.16 $197,706 - $251,174	-15,543 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$12.34 - $17.92 $647,603 - $940,441	-52,480 Reduced 77.15%	15,543 $198,000
Q2 2020 Aug 13, 2020	BUY	$12.39 - $17.33 $842,804 - $1.18 Million	68,023 New	68,023 $1.16 Million
Q1 2019 May 14, 2019	SELL	$14.41 - $19.64 $4.76 Million - $6.48 Million	-330,022 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$12.45 - $23.47 $1.5 Million - $2.82 Million	-120,302 Reduced 26.71%	330,022 $4.29 Million
Q3 2018 Nov 14, 2018	BUY	$17.57 - $23.95 $1.78 Million - $2.43 Million	101,398 Added 29.06%	450,324 $10.8 Million
Q2 2018 Aug 14, 2018	BUY	$11.6 - $19.27 $4.05 Million - $6.72 Million	348,926 New	348,926 $6.68 Million

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.